EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Allele-Specific Suppression of Variant MHC With High-Precision RNA Nuclease CRISPR-Cas13d Prevents Hypertrophic Cardiomyopathy

Ping Yang iD, Yingmei Lou, Zilong Geng, Zhizhao Guo, Shuo Wu, Yige Li iD, Kaiyuan Song, Ting Shi iD, Shasha Zhang, Junhao Xiong, Alex F Chen iD, Dali Li und 5 weitere

Circulation · 2024

DOI: 10.1161/circulationaha.123.067890 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, 2024. Verfasst von Ping Yang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Systems Biomedicine, Shanghai Center for Systems Biomedicine, Engineering Research Center of Techniques and Instruments for Diagnos…. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, CRISPR-Cas Systems, Myosin Heavy Chains, Cardiac Myosins. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Familial hypertrophic cardiomyopathy has severe clinical complications of heart failure, arrhythmia, and sudden cardiac death. Heterozygous single nucleotide variants (SNVs) of sarcomere genes such as MYH7 are the leading cause of this type of disease. CRISPR-Cas13 (clustered regularly interspaced short palindromic repeats and their associated protein 13) is an emerging gene therapy approach for treating genetic disorders, but its therapeutic potential in genetic cardiomyopathy remains unexplored. METHODS: We developed a sensitive allelic point mutation reporter system to screen the mutagenic variants of Cas13d. On the basis of Cas13d homology structure, we rationally designed a series of Cas13d variants and obtained a high-precision Cas13d variant (hpCas13d) that specifically cleaves the MYH7 variant RNAs containing 1 allelic SNV. We validated the high precision and low collateral cleavage activity of hpCas13d through various in vitro assays. We generated 2 HCM mouse models bearing distinct MYH7 SNVs and used adenovirus-associated virus serotype 9 to deliver hpCas13d specifically to the cardiomyocytes. We performed a large-scale library screening to assess the potency of hpCas13d in resolving 45 human MYH7 allelic pathogenic SNVs. RESULTS: Wild-type Cas13d cannot distinguish and specifically cleave the heterozygous MYH7 allele with SNV. hpCas13d, with 3 amino acid substitutions, had minimized collateral RNase activity and was able to resolve various human MYH7 pathological sequence variations that cause hypertrophic cardiomyopathy. In vivo application of hpCas13d to 2 hypertrophic cardiomyopathy models caused by distinct human MYH7 analogous sequence variations specifically suppressed the altered allele and prevented cardiac hypertrophy. CONCLUSIONS: Our study unveils the great potential of CRISPR-Cas nucleases with high precision in treating inheritable cardiomyopathy and opens a new avenue for therapeutic management of inherited cardiac diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicCRISPR-Cas SystemsMyosin Heavy ChainsCardiac MyosinsAnimalsMiceHumansAllelesMyocytes, CardiacDisease Models, AnimalGenetic Therapy

Stichwörter der Autor:innen

cardiomyopathy, hypertrophiccardiomyopathy, hypertrophic, familialtherapeutics

Substanzen

Myosin Heavy ChainsCardiac MyosinsMYH7 protein, humanMyh7 protein, mouse

Autor:innen und Institutionen

  • Key Laboratory of Systems Biomedicine, Shanghai Center for Systems Biomedicine, Engineering Research Center of Techniques and Instruments for Diagnosis and Treatment of Congenital Heart Disease, Institute for Developmen…
  • State Key Laboratory of Microbial Metabolism, Joint International Research Laboratory of Metabolic and Developmental Sciences, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China (T…
  • Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai,…
  • Department of Cardiology, Boston Children's Hospital, Harvard Medical School, MA (W.T.P.).
  • Harvard Stem Cell Institute, Harvard University, MA (W.T.P.).
  • School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China (Y.Z.).

ORCID-Profile: Ping Yang, Yige Li, Ting Shi, Alex F Chen, William T Pu, Yan Zhang, Bing Zhang

Zitieren

APA

Yang, P., Lou, Y., Geng, Z., Guo, Z., Wu, S., Li, Y., Song, K., Shi, T., Zhang, S., Xiong, J., Chen, A. F., Li, D., Pu, W. T., Da, L., Zhang, Y., Sun, K., & Zhang, B. (2024). Allele-Specific Suppression of Variant MHC With High-Precision RNA Nuclease CRISPR-Cas13d Prevents Hypertrophic Cardiomyopathy. Circulation. https://doi.org/10.1161/circulationaha.123.067890

Vancouver

Yang P, Lou Y, Geng Z, Guo Z, Wu S, Li Y, et al. Allele-Specific Suppression of Variant MHC With High-Precision RNA Nuclease CRISPR-Cas13d Prevents Hypertrophic Cardiomyopathy. Circulation. 2024. doi:10.1161/circulationaha.123.067890

BibTeX
@article{Yang2024,
  author = {Yang, Ping and Lou, Yingmei and Geng, Zilong and Guo, Zhizhao and Wu, Shuo and Li, Yige and Song, Kaiyuan and Shi, Ting and Zhang, Shasha and Xiong, Junhao and Chen, Alex F and Li, Dali and Pu, William T and Da, Lintai and Zhang, Yan and Sun, Kun and Zhang, Bing},
  title = {Allele-Specific Suppression of Variant MHC With High-Precision RNA Nuclease CRISPR-Cas13d Prevents Hypertrophic Cardiomyopathy},
  journal = {Circulation},
  year = {2024},
  doi = {10.1161/circulationaha.123.067890}
}
Kostenlos starten →